Author

Yamillie Ortiz

Mayo ClinicORCID 0000-0002-2002-2771Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Adam D. BassiD· 1 shared Archit Bajaj· 1 shared August J. JohniD· 1 shared Esther P. B. RodmaniD· 1 shared Gustavo BaldassarreiD· 1 shared John R. HawseiD· 1 shared Michael J. EmchiD· 1 shared Nicole A Pearson· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam D. BassORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer

Esther P. B. Rodman, Michael J. Emch, Xiaonan Hou, Archit Bajaj, Nicole A Pearson, August J. John, Yamillie Ortiz, Adam D. Bass, Saloni Singh, Gustavo Baldassarre, Scott H. Kaufmann, S. John Weroha, John R. Hawse

This study identifies lestaurtinib as a potent inhibitor of ovarian cancer, effective against resistant models, by targeting JAK/STAT signaling and synergizing with standard therapies.

npj Precision Oncology · Jul 11, 2025Peer-reviewedCancer Biology